Production (Stage)
Cyclacel Pharmaceuticals, Inc.
CYCC
$0.358
-$0.0541-13.13%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 97.25% | 42.10% | 67.56% | 40.22% | 49.24% |
| Total Depreciation and Amortization | -- | -87.50% | -85.71% | -75.00% | -75.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 795.72% | -69.81% | -72.87% | -49.86% | -50.13% |
| Change in Net Operating Assets | -312.88% | 53.30% | -175.20% | -100.05% | 257.92% |
| Cash from Operations | -572.26% | 65.32% | 24.01% | -136.32% | 92.96% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | 53.77% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -213.92% | -- | -- | -- | -- |
| Cash from Financing | 4,715.19% | 61.46% | 98.00% | 12,431.37% | -58.00% |
| Foreign Exchange rate Adjustments | -377.78% | -129.57% | 137.31% | -103.53% | -357.14% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 153.97% | 106.04% | 28.48% | 351.93% | 91.61% |